2026년 9월 16일•3분 읽기
GC Green Cross Secures IND for High‑Immunogenicity Elderly Flu Vaccine GC3114B
GC Green Cross received MFDS IND approval to start Phase 2/3 trials of its high‑immunogenicity influenza vaccine candidate GC3114B in adults 65+, targeting domestic self‑sufficiency and future NIP inclusion.